Home-based heart fitness program for high-risk AML patients undergoing stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study tests whether a structured, home-based program combining aerobic exercise and resistance training can support heart health in patients with high-risk AML undergoing transplantation. Participants perform 30 minutes of moderate aerobic activity five days a week and 15–30 minutes of strength training three days a week for up to 12 weeks, with safety monitoring and blood tests during the study. After the intervention, they are followed for 12 months to observe outcomes. The program is designed as prehabilitation to help patients better tolerate intensive therapy and reduce cardiovascular risks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older
* Ability to understand and willingness to sign a written informed consent document
* New diagnosis of acute myeloid leukemia at Fred Hutch
* High-risk patients as defined by one, or more, of the following criteria:

  * Age 65 years or older and/or
  * Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) score ≥ 3 (for patients 20 years old or older) and/or
  * CARE-BMT score ≥ 5

    * Note: HCT-CI and CARE-BMT scores will be measured at pre-screening by study staff
* Able to exercise at low to moderate intensity, as evaluated by study staff
* Access to a mobile smart phone
* Able to read and write in English

Exclusion Criteria:

* Orthopedic, neurologic, or other problems that prevent safe ambulation and protocol adherence. Information on prior falls and other recent orthopedic or neurologic problems will be used to make judgment about protocol eligibility
* Recurrence of AML or diagnosis of other invasive cancer
* Severe anemia (hemoglobin \< 7 gm/dl)
* History of severe aortic stenosis
* New York Heart Association (NYHA) class IV heart failure
* Severe pain with basic movement
* Pregnant persons
* Unable to give consent

Where it's running

• Fred Hutch/University of Washington Cancer Consortium
  Seattle, Washington, United States Recruiting

Study contacts

• Principal investigator: Alexi Vasbinder, PhD, RN — Fred Hutch/University of Washington Cancer Consortium
• Study coordinator: Alexi Vasbinder, PhD, RN
• Email: avasbind@uw.edu
• Phone: 206-221-4390

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Characterization of CD180 Protein Expression in Myeloid Blood C cancers

  This study tests how CD180 is presented on myeloid cancer cells and normal stem cells using existing patient samples from AML cases to see if it could help with diagnosis or monitoring.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07895901

• Personalized AML: Find biomarkers to predict response to venetoclax

  This study tests whether single-cell analyses can help group AML patients by biology and find biomarkers that predict who will respond to venetoclax.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07874100

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• MAX-40279 with Venetoclax and Azacitidine for unfit newly diagnosed AML

  This study tests MAX-40279 added to venetoclax and azacitidine in older or unfit adults newly diagnosed with AML to see if it is safe and shows activity.

  Recruiting Phase 2 Maxinovel Pty., Ltd. · Tianjin · NCT07743112

• Venetoclax and Azacitidine Consolidation After Remission in Intermediate-Risk AML

  We’re testing if a venetoclax-plus-azacitidine consolidation approach works as well as standard high-dose chemotherapy for adults with intermediate-risk AML who have already achieved remission and are headed to stem cell transplant.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07672262

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.